US patent sought for obesity susceptibility test:
This article was originally published in Clinica
GeneLink has filed a US patent application covering its non-invasive genetic test for assessing an individual's susceptibility to obesity. The test, which measures single-nucleotide polymorphisms in several genes, could help nutritional companies and those involved in medical, health and weight loss management offer an earlier and improved approach to obesity management, claims the Margate, New Jersey firm. Sample collection involves mailing saliva swabs to a testing laboratory. John De Phillipo, GeneLink's, chairman and CEO says the firm has already "received an overwhelming response from major weight loss and nutritional companies seeking distribution".
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.